Justin Loke, Myriam Labopin, Charles Craddock, Gérard Socié, Tobias Gedde-Dahl, Didier Blaise, Edouard Forcade, Urpu Salmenniemi, Anne Huynh, Jurjen Versluis, Ibrahim Yakoub-Agha, Hélène Labussière-Wallet, Johan Maertens, Jakob Passweg, Claude Eric Bulabois, Ludovic Gabellier, Stephan Mielke, Cristina Castilla-Llorente, Eric Deconinck, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
INTRODUCTION: For the majority of patients with acute myeloid leukemia (AML) an allogeneic stem cell transplant (SCT) in first complete remission (CR) is preferred. However, whether the number of courses required to achieve CR has a prognostic impact is unclear. It is unknown which factors remain important in patients requiring more than one course of induction to attain remission. METHODS: This Acute Leukaemia Working Party study from the European Society for Blood and Marrow Transplantation identified adults who received an allograft in first CR from either a fully matched sibling or 10/10 or 9/10 human leucocyte antigen (HLA)-matched unrelated donor (HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ)...
April 6, 2024: Cancer